Arrowhead Pharmaceuticals, Inc.
Compositions and methods for inhibiting expression of RRM2 genes
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
Status:
Grant
Type:
Utility
Filling date:
27 Feb 2018
Issue date:
14 Apr 2020